ALNY
Price
$339.80
Change
-$0.00 (-0.00%)
Updated
Jul 31 closing price
Capitalization
44.31B
83 days until earnings call
INO
Price
$1.42
Change
-$0.02 (-1.39%)
Updated
Jul 31 closing price
Capitalization
72.11M
Interact to see
Advertisement

ALNY vs INO

Header iconALNY vs INO Comparison
Open Charts ALNY vs INOBanner chart's image
Alnylam Pharmaceuticals
Price$339.80
Change-$0.00 (-0.00%)
Volume$15.17K
Capitalization44.31B
Inovio Pharmaceuticals
Price$1.42
Change-$0.02 (-1.39%)
Volume$783.71K
Capitalization72.11M
ALNY vs INO Comparison Chart in %
Loading...
ALNY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALNY vs. INO commentary
Aug 01, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALNY is a Buy and INO is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 01, 2025
Stock price -- (ALNY: $391.99 vs. INO: $1.41)
Brand notoriety: ALNY: Not notable vs. INO: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALNY: 342% vs. INO: 44%
Market capitalization -- ALNY: $44.31B vs. INO: $72.11M
ALNY [@Biotechnology] is valued at $44.31B. INO’s [@Biotechnology] market capitalization is $72.11M. The market cap for tickers in the [@Biotechnology] industry ranges from $223.48B to $0. The average market capitalization across the [@Biotechnology] industry is $2.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALNY’s FA Score shows that 1 FA rating(s) are green whileINO’s FA Score has 0 green FA rating(s).

  • ALNY’s FA Score: 1 green, 4 red.
  • INO’s FA Score: 0 green, 5 red.
According to our system of comparison, ALNY is a better buy in the long-term than INO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALNY’s TA Score shows that 4 TA indicator(s) are bullish while INO’s TA Score has 4 bullish TA indicator(s).

  • ALNY’s TA Score: 4 bullish, 4 bearish.
  • INO’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, ALNY is a better buy in the short-term than INO.

Price Growth

ALNY (@Biotechnology) experienced а +19.51% price change this week, while INO (@Biotechnology) price change was -6.29% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.13%. For the same industry, the average monthly price growth was +16.53%, and the average quarterly price growth was +40.85%.

Reported Earning Dates

ALNY is expected to report earnings on Oct 23, 2025.

INO is expected to report earnings on May 13, 2025.

Industries' Descriptions

@Biotechnology (-1.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALNY($44.3B) has a higher market cap than INO($72.1M). ALNY YTD gains are higher at: 66.585 vs. INO (-20.506). INO has higher annual earnings (EBITDA): -93.37M vs. ALNY (-152.58M). ALNY has more cash in the bank: 2.63B vs. INO (68.4M). INO has less debt than ALNY: INO (11.3M) vs ALNY (1.3B). ALNY has higher revenues than INO: ALNY (2.35B) vs INO (283K).
ALNYINOALNY / INO
Capitalization44.3B72.1M61,442%
EBITDA-152.58M-93.37M163%
Gain YTD66.585-20.506-325%
P/E RatioN/AN/A-
Revenue2.35B283K829,682%
Total Cash2.63B68.4M3,848%
Total Debt1.3B11.3M11,522%
FUNDAMENTALS RATINGS
ALNY vs INO: Fundamental Ratings
ALNY
INO
OUTLOOK RATING
1..100
196
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
50
Fair valued
PROFIT vs RISK RATING
1..100
14100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
4194
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

INO's Valuation (50) in the Medical Specialties industry is somewhat better than the same rating for ALNY (99) in the Biotechnology industry. This means that INO’s stock grew somewhat faster than ALNY’s over the last 12 months.

ALNY's Profit vs Risk Rating (14) in the Biotechnology industry is significantly better than the same rating for INO (100) in the Medical Specialties industry. This means that ALNY’s stock grew significantly faster than INO’s over the last 12 months.

INO's SMR Rating (98) in the Medical Specialties industry is in the same range as ALNY (100) in the Biotechnology industry. This means that INO’s stock grew similarly to ALNY’s over the last 12 months.

ALNY's Price Growth Rating (41) in the Biotechnology industry is somewhat better than the same rating for INO (94) in the Medical Specialties industry. This means that ALNY’s stock grew somewhat faster than INO’s over the last 12 months.

ALNY's P/E Growth Rating (100) in the Biotechnology industry is in the same range as INO (100) in the Medical Specialties industry. This means that ALNY’s stock grew similarly to INO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALNYINO
RSI
ODDS (%)
Bearish Trend 1 day ago
75%
Bullish Trend 1 day ago
78%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
86%
MACD
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
78%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
71%
Bearish Trend 1 day ago
89%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
73%
Bearish Trend 1 day ago
87%
Advances
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 9 days ago
77%
Declines
ODDS (%)
Bearish Trend 11 days ago
65%
Bearish Trend 7 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
72%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
74%
Bearish Trend 1 day ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
ALNY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
ETO27.400.04
+0.15%
Eaton Vance Tax-Advantaged Global Div Oppor Fund
BEGS32.880.02
+0.07%
Rareview 2X Bull Cryptoccy & Prc Mtl ETF
FV60.69-0.02
-0.03%
First Trust Dorsey Wright Focus 5 ETF
BBP61.53-0.19
-0.30%
Virtus LifeSci Biotech Products ETF
LSAF42.23-0.35
-0.83%
LeaderSharesTM AlphaFactor® US Cr Eq ETF

INO and

Correlation & Price change

A.I.dvisor indicates that over the last year, INO has been loosely correlated with AXON. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if INO jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INO
1D Price
Change %
INO100%
-1.74%
AXON - INO
53%
Loosely correlated
+0.97%
ARRY - INO
52%
Loosely correlated
-2.11%
RPTX - INO
52%
Loosely correlated
-1.31%
BCYC - INO
47%
Loosely correlated
+0.12%
ALNY - INO
42%
Loosely correlated
+15.36%
More